Cempra to Present Solithromycin IV Data at ATS 2016
12. Mai 2016 16:05 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., May 12, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Reports First Quarter 2016 Financial Results and Provides Corporate Update
01. Mai 2016 17:05 ET
|
Melinta Therapeutics, Inc.
NDA submissions completed for solithromycin intravenous and oral capsule formulations in the treatment of community-acquired pneumonia Management to host webcast and conference call tomorrow at...
Cempra Completes NDA Submissions for Solithromycin in the Treatment of Community-Acquired Bacterial Pneumonia
01. Mai 2016 17:00 ET
|
Melinta Therapeutics, Inc.
Solithromycin is designated by FDA as a Qualified Infectious Disease Product FDA has granted Priority Review and Fast Track designation for solithromycin IV and capsules for the treatment of CABP ...
Cempra to Report First Quarter 2016 Financial Results
25. April 2016 07:30 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., April 25, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra to Present at the Needham and Company 15th Annual Healthcare Conference
06. April 2016 07:30 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., April 06, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra to Present Data on Solithromycin at ECCMID
04. April 2016 07:30 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., April 04, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra to Participate in Nature's Webcast on Combating Antibiotic Resistance on March 9
08. März 2016 16:10 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., March 08, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Authorized to Receive Funds From BARDA for a Phase 2/3 Clinical Trial of Solithromycin in Pediatric Patients
07. März 2016 07:00 ET
|
Melinta Therapeutics, Inc.
Phase 2/3 Pivotal Trial Will Test Intravenous, Oral Capsule and Oral Suspension Formulations of Solithromycin in Pediatric Patients From Age 2 Months to 17 Years Cempra to Receive $25.5...
Cempra to Present at the Cowen and Company 36th Annual Healthcare Conference
29. Februar 2016 07:30 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update
24. Februar 2016 16:05 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Feb. 24, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics in the face of rising antibiotic resistant...